1 |
Javitt DC, Spencer KM, Thaker GK, et al. Neurophysiological biomarkers for drug development in schizophrenia[J]. Nat Rev Drug Discov, 2008, 7(1): 68-83.
|
2 |
Michie PT, Malmierca MS, Harms L, et al. Understanding the neurobiology of MMN and its reduction in schizophrenia[J]. Biol Psychol, 2016, 116: 1-3.
|
3 |
Adell A. Brain NMDA receptors in schizophrenia and depression[J]. Biomolecules, 2020, 10(6): 947.
|
4 |
Wu JQ, Green MJ, Gardiner EJ, et al. Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: a transcriptome analysis[J]. Brain Behav Immun, 2016, 53: 194-206.
|
5 |
Harada E, Satoi Y, Kikuchi T, et al. Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression[J]. Neuropsychiatr Dis Treat, 2016, 12: 1599-1607.
|
6 |
Donaldson KR, Novak KD, Dan FT, et al. Associations of mismatch negativity with psychotic symptoms and functioning transdiagnostically across psychotic disorders[J]. J Abnorm Psychol, 2020, 129(6): 570-580.
|
7 |
Koshiyama D, Kirihara K, Tada M, et al. Reduced auditory mismatch negativity reflects impaired deviance detection in schizophrenia[J]. Schizophr Bull, 2020, 46(4): 937-946.
|
8 |
Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis[J]. Biol Psychiatry, 2012, 71(2): 98-104.
|
9 |
Chen J, Zhang Y, Wei DH, et al. Neurophysiological handover from MMN to P3a in first-episode and recurrent major depression[J]. J Affect Disord, 2015, 174: 173-179.
|
10 |
Toyomaki A, Kusumi I, Matsuyama T, et al. Tone duration mismatch negativity deficits predict impairment of executive function in schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(1): 95-99.
|
11 |
Magno E, Yeap S, Thakore JH, et al. Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia[J]. Biol Psychiatry, 2008, 64(5): 385-391.
|
12 |
Bonetti L, Haumann NT, Vuust P, et al. Risk of depression enhances auditory Pitch discrimination in the brain as indexed by the mismatch negativity[J]. Clin Neurophysiol, 2017, 128(10): 1923-1936.
|
13 |
Anaya C, Torrent C, Caballero FF, et al. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life[J]. Acta Psychiatr Scand, 2016, 133(5): 386-398.
|
14 |
Nagai T, Kirihara K, Tada M, et al. Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis[J]. Sci Rep, 2017, 7(1): 2258.
|
15 |
顾君, 徐清, 刘晓伟, 等. 抑郁症与单纯型精神分裂症鉴别诊断中定量脑电图的应用价值研究[J]. 中国全科医学, 2014, 17(20): 2312-2316.
|
16 |
Koshiyama D, Kirihara K, Tada M, et al. Association between mismatch negativity and global functioning is specific to duration deviance in early stages of psychosis[J]. Schizophr Res, 2018, 195: 378-384.
|
17 |
Koshiyama D, Kirihara K, Tada M, et al. Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis[J]. Schizophr Res, 2017, 190: 32-38.
|
18 |
Murphy TK, Haigh SM, Coffman BA, et al. Mismatch negativity and impaired social functioning in long-term and in first episode schizophrenia spectrum psychosis[J]. Front Psychiatry, 2020, 11: 544.
|
19 |
Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients[J]. Mol Psychiatry, 2006, 11(2): 118-119.
|
20 |
Qiao ZX, Yu YM, Wang L, et al. Impaired pre-attentive change detection in major depressive disorder patients revealed by auditory mismatch negativity[J]. Psychiatry Res, 2013, 211(1): 78-84.
|
21 |
Kaut O, Schmitt I, Hofmann A, et al. Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression[J]. Eur Arch Psychiatry Clin Neurosci, 2015, 265(4): 331-341.
|
22 |
Jaso BA, Niciu MJ, Iadarola ND, et al. Therapeutic modulation of glutamate receptors in major depressive disorder[J]. Curr Neuropharmacol, 2017, 15(1): 57-70.
|
23 |
Raith H, Schuelert N, Duveau V, et al. Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice[J]. Neuropharmacology, 2020, 171: 108072.
|
24 |
Salisbury DF, Shafer AR, Murphy TK, et al. Pitch and duration mismatch negativity and heschl's gyrus volume in first-episode schizophrenia-spectrum individuals[J]. Clin EEG Neurosci, 2020, 51(6): 359-364.
|
25 |
Mu Z, Chang Y, Xu J, et al. Pre-attentive dysfunction of musical processing in major depressive disorder: a mismatch negativity study[J]. J Affect Disord, 2016, 194: 50-56.
|
26 |
He W, Chai H, Zheng LL, et al. Mismatch negativity in treatment-resistant depression and borderline personality disorder[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2010, 34(2): 366-371.
|
27 |
Bissonnette JN, Francis AM, Hull KM, et al. MMN-indexed auditory change detection in major depressive disorder[J]. Clin EEG Neurosci, 2020, 51(6): 365-372.
|